Pearl River Capital’s Aerie Pharmaceuticals AERI Stock Holding History

Pearl River Capital’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-1,648	Closed	-$59K	–	894
2018 Q4	$59K	Buy	+1,648	New	+$77.3K	0.27%	106

Other funds holding AERI

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Pearl River Capital's AERI Position: Q1 2019 in Review

Pearl River Capital sold out of Aerie Pharmaceuticals (AERI) in Q1 2019, closing a stake of 1,648 shares — an estimated $59K sold.

Pearl River Capital first reported a position in AERI in Q4 2018 and held it in 1 quarter. The position peaked at $59K in Q4 2018. 176 funds tracked by Wall St. Rank hold AERI as of Q1 2019.

Pearl River Capital reported no remaining Aerie Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Pearl River Capital sold 1,648 Aerie Pharmaceuticals shares in Q1 2019, an estimated $59K.
Pearl River Capital first reported a position in Aerie Pharmaceuticals in Q4 2018 and held it in 1 quarter.
Pearl River Capital's Aerie Pharmaceuticals position peaked at $59K in Q4 2018.
176 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q1 2019.

Based on Pearl River Capital's 13F filing for Q1 2019, filed 2 May 2019.